Bruker Announces Key Innovations for Multiplexed Spatial Proteomics and Unbiased Multiomic Imaging for Cancer Research

Rhea-AI Summary

Bruker Corporation (Nasdaq: BRKR) has unveiled innovative technologies at the AACR Annual Meeting 2022, focusing on spatial multiomics and single-cell proteomics for cancer research. Key launches include the MALDI HiPLEX-IHC tissue imaging solution, which integrates protein mapping with small molecule imaging, and the CellScape™ platform for high-precision spatial proteomics. The timsTOF fleX platform can identify over 13,000 proteins, advancing the capabilities in cancer profiling. These advancements position Bruker to enhance cancer research methodologies significantly.

Positive

• Launch of MALDI HiPLEX-IHC for advanced tissue imaging and protein profiling.
• Introduction of CellScape™ platform enhancing spatial proteomics with single-cell resolution.
• Ability of timsTOF fleX to identify over 13,000 proteins, improving cancer research efficacy.

Negative

• None.

• Bruker launches novel MALDI HiPLEX-IHC tissue imaging solution for timsTOF fleX using AmberGen’s HiPLEX-IHC peptide code antibody probes, combined with unbiased lipidomics, glycomics and metabolomics tissue imaging
• New Canopy CellScape™ single cell, highly quantitative spatial proteomic ChipCytometry™ platform features fully automated iterative staining using open-source antibodies for virtually unlimited immuno-oncology marker analysis on whole tissue sections for TME and metastasis research
• For cancer cell-line assays and biopsy proteomics research, dia-PASEF® on the timsTOF 4D platform can identify up to 13,000 proteins with 1% FDR (false discovery rate); identifies and quantifies more than 8000 proteins in 35 minutes from ultra-deep libraries; over 25% more phosphopeptides identified using novel TIMScore algorithm
• Novel timsTOF SCP platform enables unbiased single cell proteomics research, an essential complement to sc-RNA-seq for spatial biology cancer research
• Unique high-throughput timsTOF Pro 2 platform enables liquid biopsy biomarker research with various unbiased and deep plasma proteomics and PTM methods

NEW ORLEANS--(BUSINESS WIRE)-- At the AACR Annual Meeting 2022, Bruker Corporation (Nasdaq: BRKR) launched and exhibited unique and novel capabilities for spatial multiomics, single-cell proteomics, and cell-line, tissue and plasma proteomics cancer research.

Sagittal mouse brain section showing MALDI HiPLEX IHC mass tagged antibody locations in fresh frozen tissue overlayed with an unbiased small molecule image showing the presence of ganglioside and sulfatide lipids. The lower inset spectrum shows detected masses of the photocleaved peptide labels. (Photo: Business Wire)

Following up on Bruker’s recent strategic investment in AmberGen Inc., Bruker is announcing a partnership for the application of Ambergen Miralys™ peptide-code antibody kits for the Bruker timsTOF flex novel MALDI HiPLEX-IHC workflow for targeted protein expression profiling in tissue. By combining peptide-code mass-reporting antibody probes for protein recognition with Bruker’s comprehensive MALDI imaging workflows, researchers can produce highly multiplexed images of target proteins in a wide field-of-view up to a standard slide.

Bruker’s timsTOF fleX platform integrates MALDI HiPLEX-IHC protein mapping with unbiased small molecule imaging (lipids, glycans, metabolites, xenobiotics) from the same tissue section, a new and unique multiomics capability for cancer cell-line, tissue and TME imaging research from fresh frozen or formalin-fixed paraffin-embedded (FFPE) sections.

Dr. Michael L. Easterling, Bruker Director of Imaging Life Sciences Mass Spectrometry, commented: “Spatial protein expression mapping can elucidate processes in immuno-oncology, and in TME and metastasis research. The MALDI HiPLEX IHC workflow based on AmberGen’s peptide-encoded antibody panels provides targeted protein localization and adds the capability to map important lipids, glycan and metabolite markers on the same tissue section.

Additionally, Bruker demonstrated the new CellScape^TM instrument for high-precision targeted spatial proteomics, recently launched by their Canopy Biosciences division. Canopy Biosciences’ CellScape is the latest generation ChipCytometry^TM instrument, which enables high-plex spatial imaging and quantification of protein biomarkers in a wide variety of sample types with single-cell and sub-cellular resolution. CellScape further improves spatial resolution, offers up to 8x higher throughput, and walkaway automation. CellScape is unique for quantitative biology with 8-log extremely high dynamic range (HDR) imaging to quantify both low and high expressing proteins in the same sample, solving a key challenge inherent in high-plex imaging. Applications in cancer biology are abundant and include spatial phenotyping of the diverse tumor and immune cell types in the tumor microenvironment (TME).

Canopy also featured their Spatial Immune Profiling kits for the ChipCytometry platform. The Spatial Immune Profiling kit is a quantitative, multiplexed assay for FFPE tissues developed to provide ready-to-use pre-validated antibody reagents for ChipCytometry researchers, e.g., for immuno-oncology. The kits enable researchers to skip assay development and move straight into performing their translational and clinical research assays.

About Bruker Corporation (Nasdaq: BRKR)

Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular and cell biology research, in applied and pharma applications, in microscopy and nanoanalysis, as well as in industrial applications. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. Please visit www.bruker.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220411005644/en/

Media Contact

Petra Scheffer

Bruker Daltonics Marketing Communications

T: +49 (421) 2205-2843

E: petra.scheffer@bruker.com



Investor Relations Contact

Justin Ward

Sr. Director Investor Relations & Corp Development

T: +1 (978) 663–3660, ext. 1479

E: Investor.Relations@bruker.com

Source: Bruker Corporation

FAQ

What is the new technology launched by Bruker at the AACR Annual Meeting 2022?

Bruker launched the MALDI HiPLEX-IHC tissue imaging solution and the CellScape™ platform for proteomics.

How does the <b>timsTOF fleX</b> platform enhance cancer research?

The timsTOF fleX platform can identify over 13,000 proteins, facilitating advanced cancer profiling.

What capabilities does the <b>CellScape™</b> platform offer?

The CellScape™ platform enables high-plex spatial imaging and quantification of protein biomarkers with single-cell resolution.

What are the benefits of the <b>MALDI HiPLEX-IHC</b> technology?

It allows for targeted protein localization and simultaneous mapping of lipids, glycans, and metabolites from the same tissue sample.